Robert F. Kennedy Jr. will be pulling his investments from two biotechs if he is confirmed to lead the U.S. Department of ...

Following last year’s launches of several all-in-one CRO offerings, Lindus Health is starting 2025 strong by closing a $55 ...

Beta Bionics has set the terms for its plan to go public, with a goal of raising at least $114 million to support its ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate’s potential to help resolve the opioid crisis. | Tris Pharma has pointed to a phase 3 win for its pain ...

A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...